Imaging
Cerebellar Degeneration
- Preliminary Diagnosis: Cerebellar Degeneration
-
I. What imaging technique is first-line for this diagnosis?
- II. Describe the advantages and disadvantages of this technique for diagnosis of cerebellar degeneration.
-
III. What are the contraindications for the first-line imaging technique?
-
IV. What alternative imaging techniques are available?
- V. Describe the advantages and disadvantages of the alternative techniques for diagnosis of cerebellar degeneration.
- VI. What are the contraindications for the alternative imaging techniques?
Preliminary Diagnosis: Cerebellar Degeneration
I. What imaging technique is first-line for this diagnosis?
Noncontrast CT of the brain
II. Describe the advantages and disadvantages of this technique for diagnosis of cerebellar degeneration.
Advantages
Less expensive than MRI
Faster to peform than MRI
Disadvantages
Exposes patients to ionizing radiation.
III. What are the contraindications for the first-line imaging technique?
May be contraindicated in pregnant patients.
IV. What alternative imaging techniques are available?
Contrast MRI of the brain.
V. Describe the advantages and disadvantages of the alternative techniques for diagnosis of cerebellar degeneration.
Contrast MRI of the brain
Advantages
Able to better detect any underlying cerebellar abnormalities with greater specificity and sensitivity that may be associated with focal degeneration
Allows exquisite soft tissue visualization
Disadvantages
Less adept at characterizing the surrounding osseous structures
Subject to motion artifact due to extensive length of the examination degrading image quality
VI. What are the contraindications for the alternative imaging techniques?
Contrast MRI of the brain
Contraindicated in patients with non-MR-compatible hardware
Copyright © 2017, 2014 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
ONA Articles
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- Takeda to Collaborate With MSKCC on CAR-T Therapies for Multiple Myeloma
- Sequential Immunotherapy, Targeted Therapy Linked to Cutaneous Adverse Events in Advanced Melanoma
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- NIH Establishes Educational Program on Genomics, Genetics for Oncology Nurses
- Oncology Nurse Navigation Facilitates Timely Treatment of Pancreatic Cancer
- Helping Patients Face the Challenge of Eating Healthy During Cancer Treatment
- Oncology Nurses Weigh In on Their Patient-Centered Communication Practices, Needs
- Substitute for Lidocaine
- CART cell therapy for prostate cancer: status and promise
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- Survey Demonstrates Relationship Between Symptom Burden, Medical Disability Leave Among Myeloproliferative Neoplasms
- A Review of Clinical Outcomes in Patients With Early-Stage Burkitt Lymphoma
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- USPSTF Still Recommends Against Pancreatic Cancer Screening
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
Bone Cancer | Regimens | Drugs |
Brain Cancer | Regimens | Drugs |
Breast Cancer | Regimens | Drugs |
Endocrine Cancer | Regimens | Drugs |
Gastrointestinal Cancer | Regimens | Drugs |
Genitourinary Cancer | Regimens | Drugs |
Gynecologic Cancer | Regimens | Drugs |
Head and Neck Cancer | Regimens | Drugs |
Hematologic Cancer | Regimens | Drugs |
Lung Cancer | Regimens | Drugs |
Other Cancers | Regimens | |
Rare Cancers | Regimens | |
Skin Cancer | Regimens | Drugs |